European approval for Pfizer’s psoriatic arthritis combo

Sun Pharma bolsters dermatology offering with Pola Pharma buy
Credit: Hriana

Pfizer has picked up European approval for Xeljanz in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis in adult patients.

Xeljanz is the first and only oral Janus kinase inhibitor to be approved in the European Union (EU) for the treatment of adults with active PsA.

In 2017, Xeljanz in combination with MTX was approved in the EU for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs.

The approval from the European Commission was based on a submission package that included data from the Phase 3 Oral Psoriatic Arthritis TriaLs (OPAL) clinical development program in PsA.